New research identifies the liver protein PTPRD as a key regulator of metabolic liver disease. Reduced levels of PTPRD disrupt glucose and lipid metabolism, promote liver fat accumulation, and impair ...

The therapy is the fourth clinical-stage programme derived from the company’s chemoproteomics discovery platform.

The protein STAT3 is often overactive in these cells. Attempts to inhibit its activity therapeutically have—so far—not been ...

These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins. In addition, there is inhibition of expression of ...

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer ...

New research from Juntendo University, Japan, reveals that voluntary exercise prevents hypertension (high blood pressure) by ...